School of Medicine
Showing 1-36 of 36 Results
-
Steven Artandi, MD, PhD
Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
-
Ami Bhatt
Associate Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
-
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.
-
Rondeep Brar
Clinical Associate Professor, Medicine - Hematology
BioAs the Medical Director of the Stanford Cancer Center and Associate Director for Clinical Care at the Stanford Cancer Institute, it is my privilege to partner with my colleagues in advancing innovative research alongside high quality, coordinated, and compassionate care.
I aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma. I aim to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic. -
Robert Diep, MD
Clinical Assistant Professor, Medicine - Hematology
BioDr. Diep is a board-certified, fellowship-trained hematologist with Stanford’s Hematology Program and Hematologic Cancer Program. He is also a clinical assistant professor with the Department of Medicine, Division of Hematology.
He diagnoses and treats patients with a wide range of nonmalignant hematology conditions. His special interests include clotting disorders, bleeding disorders, hemoglobinopathies, and disorders affecting blood count. Subspecialty interests include anticoagulation and thrombosis.
Dr. Diep’s practice style emphasizes shared decision-making by building patient-physician relationships and using the best available evidence to create treatment plans. He is passionate about improving care for patients with blood disorders and has helped expand access to hematology care by launching an electronic consult service for primary care providers.
Dr. Diep’s research interests include anticoagulation, thrombosis, and bleeding disorders. He has participated in research projects that have received funding from the National Heart, Lung, and Blood Institute.
Dr. Diep has published in multiple peer-reviewed journals, and has presented to his peers at national and regional meetings.
He is a member of the American Society of Hematology, American Society of Clinical Oncology, Hemostasis and Thrombosis Research Society, International Society of Hemostasis and Thrombosis, and Anticoagulation Forum. Dr. Diep serves as quality director for the Division of Hematology. -
Tamara Dunn
Clinical Associate Professor, Medicine - Hematology
BioDr. Tamara Dunn is a clinical associate professor in the Division of Hematology at the Stanford University School of Medicine. She is a clinician with a special interest in medical education, diversity, equity, and inclusion. Specifically, she is committed to improving workforce diversity and creating inclusive workplaces. She is currently the Program Director for the Stanford Hematology/Oncology Fellowship and one of the Associate Chairs of Diversity and Inclusion for the Department of Medicine at Stanford. She is a member of the inaugural American Society of Hematology (ASH) Ambassador Cohort and serves on the ASH Women in Hematology committee, which she co-chairs. She is on the steering committee and is a mentor for Stanford’s Leadership Education in Advancing Diversity (LEAD) program. She takes pride in treating underserved veterans at the Palo Alto Veterans Hospital, where she sees both classical and malignant hematology. Outside of medicine she enjoys singing, dancing, sports (Go Chiefs! Go Warriors!), board games, movies, and spending time with friends and family including her 3 young children, spouse, and energetic vizsla Casey.
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, and other hematologic malignancies. As a clinical scientist, Dr. Fakhri is dedicated to caring for patients, teaching trainees, and researching novel therapies for patients with CLL/SLL. Dr. Fakhri has co-authored numerous publications on topics including CLL, novel targeted agents, and cellular therapies for patients with hematologic malignancies. Currently, Dr. Fakhri is the director of the CLL clinical trial portfolio at Stanford, and serves on the National Comprehensive Cancer Network CLL panel.
-
Lawrence Tim Goodnough
Professor of Pathology and of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsImproving blood utilization
Promoting alternatives to blood transfusion
Quality improvements -
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Neel K. Gupta
Clinical Associate Professor, Medicine - Oncology
Clinical Assistant Professor, Medicine - HematologyCurrent Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.
-
David Iberri
Clinical Assistant Professor, Medicine - Hematology
BioDr. Iberri is a hematologist who specializes in the treatment of multiple myeloma, Waldenström macroglobulinemia, and other blood and bone marrow disorders. He is actively involved in clinical research evaluating novel agents in hematologic malignancies. His research interests include the development and application of biomarkers to select patients most likely to benefit from therapy, and in the development of blood tests to reduce the need for bone marrow biopsies in myeloma disease monitoring.
-
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly InterestsLow molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Michaela Liedtke
Associate Professor of Medicine (Hematology)
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis -
Ravi Majeti MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
-
Gabriel Mannis
Associate Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
-
Bruno Medeiros
Adjunct Clinical Associate Professor, Medicine - Hematology
Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
-
Giselle (Ghazal) Salmasi, MD
Clinical Associate Professor, Medicine - Hematology
BioDr. Salmasi is a board-certified, fellowship-trained hematologist. She treats patients in the Hematology Program and the Hematologic Cancer Program at Stanford Health Care. Dr. Salmasi is the associate clinical chief for classical hematology. She is also a clinical associate professor in the Division of Hematology, Department of Medicine at Stanford University School of Medicine.
She treats a wide range of blood disorders and blood cancers. Her clinical/research interests include immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Dr. Salmasi understands that patients need social and emotional support along with medical care. She founded the earliest adolescent and young adult survivorship support groups in Santa Cruz, California, and Toronto, Canada. Dr. Salmasi is also dedicated to training future doctors in providing excellent hematologic care.
Dr. Salmasi was the medical co-investigator for a national phase 3 clinical trial of endovascular therapy for treating chronic venous thrombosis.
Her research has appeared in the Leukemia & Lymphoma journal and the Transfusion and Apheresis Science journal. Dr. Salmasi’s publications include articles and a chapter about lymphoma. She has also reviewed articles for the Biology of Blood and Marrow Transplantation journal and the Journal of Clinical Oncology.
Dr. Salmasi is a member of the American Society of Hematology. -
William Shomali
Clinical Assistant Professor, Medicine - Hematology
BioDr. Shomali is a clinical assistant professor of Hematology at Stanford University School of Medicine. He is board certified in hematology & medical oncology.
Dr. Shomali specializes in the treatment of blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes. He aims to provide compassionate, personalized, and evidence-based care to each patient.
Dr. Shomali received his medical degree from the University of Jordan, followed by a postdoctoral fellowship at MD Anderson Cancer Center where he studied infections in cancer patients and the role of biomarkers in defining tumor fever. He completed his residency training in Internal Medicine at the Cleveland Clinic Foundation where he served as a Chief Medical Resident. He then joined Stanford University for his combined Hematology & Oncology fellowship training.
Dr. Shomali’s research interests include the study of novel agents in myeloproliferative neoplasms and myelodysplastic syndromes. He developed investigator-initiated clinical trials for patients with eosinophilic neoplasms and advanced myelofibrosis. In addition, he co-authored several papers and book chapters discussing the care of patients with cancer. His work has been presented in national meetings and published in peer reviewed journals including Blood, American Journal of Hematology, British Journal of Hematology, Leukemia & Lymphoma, and Cancer.
Among his honors, Dr. Shomali received the Cleveland Clinic Excellence in Teaching Award and was named to the Alpha Omega Alpha Medical Honor Society. He has received a Young Investigator Award from the Conquer Cancer Foundation, an NIH Institutional National Research Service Award, and a Stanford Cancer Institute Fellowship Award.
Dr. Shomali is a member of the American Society of Hematology and the American Society of Clinical Oncology. -
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
Current Research and Scholarly InterestsMy main research and clinical interests include molecular pathogenesis of acquired cytopenias, genetic testing for inherited non-malignant hematologic disorders, next-generation sequencing approaches to T and B cell clonality testing, somatic mutations in cancer and assessment of minimal residual disease in cancer patients.
-
Tian Yi Zhang, MD, PhD
Assistant Professor of Medicine (Hematology)
BioDr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology.
In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options.
Her research activities include conducting early phase clinical trials, investigator initiated clinical trials (IITs), studying the immune repertoire in patients with myeloid malignancies, and exploring cholesterol metabolic dependencies of acute myeloid leukemia (AML).
She was the recipient of an A.P. Giannini Foundation fellowship award, which supports innovative research. The award helped fund Dr. Zhang’s study of how AML cells interact with other cells in bone marrow. A significant finding confirmed that AML cells secrete a protein that suppresses the production of red blood cells, the same protein that causes inflammation in disorders such as rheumatoid arthritis and Crohn’s disease.
Her many other honors include the National Cancer Institute Career Development (K08) Award, the American Society of Hematology (ASH) Research Training Award for Fellows, Stanford Cancer Institute - American Cancer Society (SCI-ACS) Pilot Grant and Best ASH Abstract Award two years in a row. She also has earned recognition from the National Institutes of Health and American College of Physicians.
She has published her research findings on topics such as advanced therapy for high-risk myelodysplastic syndromes and reversal of bone marrow failure induced by AML. Her work has appeared in Leukemia & Lymphoma, Science Translational Medicine, Cancer Research, the Journal of Clinical Investigation, Journal of Immunology, and elsewhere.
Dr. Zhang is a member of the American Association of Cancer Research and American Society of Hematology. She advises and mentors Stanford medical students, residents and fellows. She delivers invited lectures to faculty and fellows. In addition, she has been an invited speaker on the topic of acute myeloid leukemia at the Association of Northern California Oncologists Update on Hematological Malignancies.
